Opinion|Videos|March 4, 2024
Innovation vs Access: Supporting Underserved Communities
Pam R. Taub, MD, FACC, FASPC, highlights disparities in access to effective evidence-based therapies for minorities, emphasizing the gap between innovation and access.
Episodes in this series
Related to this article
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
A follicular lymphoma survivor shares axi-cel CAR T-cell therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improve quality of life.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.